IMGT (XKRX:456570) Payments of Debt : ₩0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is IMGT Payments of Debt?

IMGT's Payments of Debt for the six months ended in Dec. 2023 was ₩0.00 Mil.

IMGT's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2023 was ₩0.00 Mil.

IMGT Payments of Debt Historical Data

The historical data trend for IMGT's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMGT Payments of Debt Chart

IMGT Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Payments of Debt

IMGT Semi-Annual Data
	Dec20	Dec21	Dec22	Dec23
Payments of Debt	-	-	-	-

IMGT Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2023 was ₩0.00 Mil.

IMGT Payments of Debt Related Terms

Thank you for viewing the detailed overview of IMGT's Payments of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

IMGT (XKRX:456570) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IMGT Corp Ltd (XKRX:456570) » Definitions » Payments of Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

172 Dolma-ro,, 408, Healthcare Innovation Park, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13605

Website

http://www.imgt.co.kr

IMGT Corp Ltd develops a focused ultrasound-based drug delivery platform for intractable diseases. It is developing nanomedicines and focused ultrasound medical devices that respond to focused ultrasound. The firm has two pipeline products IMD20 and IMP101. IMD20 is a FUS device developed for chronic pain as a product with reduced size and output from IMD10 developed for cancer treatment. IMP101 is a nanoparticle used for hepatocarcinoma embolization.

IMGT (XKRX:456570) Headlines

No Headlines